ARYx.com
Print page
Email page
Download PDF
« Previous Release | Next Release »
FREMONT, Calif., Aug 06, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss second quarter 2008 results will be held on Wednesday, August 13, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 866-314-4483
Dial In (International): 617-213-8049
Passcode: 96886706
Preregistration is not required. This call is also being webcast by Thomson/CCBN and can be accessed at ARYx Therapeutics' web site at www.aryx.com or through Thomson at www.earnings.com. Replays of the call will be available through August 27, 2008 by dialing 888-286-8010 (617-801-6888 Internationally), passcode 68288393.
About ARYx Therapeutics
ARYx Therapeutics Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, ATI-5923; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, ATI-2042; a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.
SOURCE: ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. David Nagler, 510-585-2200 ext. 211
Copyright Business Wire 2008
News Provided by COMTEX